

Supplemental Table 5. Proportion of Subjects With Detectable Levels of IL-1 β Before and 2 and 4 Weeks After Initiating Treatment With Placebo or Lutikizumab 200 mg Every 2 Weeks

Proportion of Subjects With Detectable Levels of IL-1β, n/N (%)	Baseline for Week 2	At Week 2	Baseline for Week 4	At Week 4
Placebo	21/64 (33)	18/64 (28)	21/61 (34)	17/61 (28)
Lutikizumab	23/61 (38)	1/61 (2)	20/57 (35)	0/57 (0)

IL-1 β =interleukin-1 β .